MDPI and ACS Style
Romaniello, D.; Marrocco, I.; Belugali Nataraj, N.; Ferrer, I.; Drago-Garcia, D.; Vaknin, I.; Oren, R.; Lindzen, M.; Ghosh, S.; Kreitman, M.;
et al. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers 2020, 12, 2394.
https://doi.org/10.3390/cancers12092394
AMA Style
Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M,
et al. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers. 2020; 12(9):2394.
https://doi.org/10.3390/cancers12092394
Chicago/Turabian Style
Romaniello, Donatella, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman,
and et al. 2020. "Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor" Cancers 12, no. 9: 2394.
https://doi.org/10.3390/cancers12092394